Table 3 Cytogenetic findings in patients with or without therapy-related myeloid neoplasms
From: Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies
Without therapy-related myeloid neoplasm | With therapy-related myeloid neoplasm | P | |
|---|---|---|---|
Number of patients | 71 (77%) | 21 (23%) | |
Karyotype prior to cytotoxic therapy | |||
Normal diploid | 30 (42%) | 8 (38%) | |
Abnormal | 11 (16%) | 0 (0%) | |
Not available | 30 (42%) | 13 (62%) | |
Intervala (months) | 56 (5–213) | 65 (9–210) | 0.4838 |
Del(20q) clone | |||
Clonal size (metaphases, %) | 25 (10–100) | 60 (10–100) | <0.0001 |
Detectable times | 2 (1–5) | 6 (1–9) | <0.0001 |
Duration (months) | 10 (1–76) | 24 (4–81) | 0.0487 |
Clone of del(20q) status during follow-up | 0.0006 | ||
Disappeared | 13 (18%) | 2 (10%) | |
Persistent | 31 (44%) | 15 (71%) | |
Unknown | 27 (38%) | 4 (19%) | |
Del(20q) breakpoints | 0.0004 | ||
20q11.2q13.3 | 45 (63%) | 13 (62%) | |
20q11.2q13.1 | 17 (24%) | 1 (5%) | |
20q11.2 | 9 (13%) | 7 (33%) | |
